Epizyme reported $38.97M in Current Liabilities for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Agios Pharmaceuticals AGIO:US $ 48.4M 2.6M
Amarin AMRN:US $ 361.57M 61M
Amgen AMGN:US $ 12618M 268M
Avrobio Inc AVRO:US $ 17.13M 2.26M
Biogen BIIB:US $ 5018M 1071.4M
Bluebird Bio BLUE:US $ 148.86M 5.97M
Cerulean Pharma CERU:US $ 16.4M 0.34M
Daiichi Sankyo 4568:JP Y 406816M 11548M
Eisai 4523:JP Y 301894M 11439M
Epizyme EPZM:US $ 38.97M 6.23M
Exelixis EXEL:US $ 289.08M 48.51M
Gilead Sciences GILD:US $ 9220M 662M
GlaxoSmithKline GSK:LN 37835M 13557M
Glaxosmithkline GSK:US $ 37835M 13557M
Karyopharm Therapeutics KPTI:US $ 62.54M 3.8M
Macrogenics MGNX:US $ 50.88M 16.22M
Mirati Therapeutics MRTX:US $ 119.15M 4.42M
Novartis NVS:US $ 27646M 2161M
Novartis NOVN:VX SF 27646M 2161M
Regeneron Pharmaceuticals REGN:US $ 3033.9M 26.3M
Seattle Genetics SGEN:US $ 608.52M 77.23M
Spectrum Pharmaceuticals SPPI:US $ 39.21M 14.02M
Vertex Pharmaceuticals VRTX:US $ 2556.2M 376M
Xencor XNCR:US $ 75.04M 14.1M